These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1925812)

  • 1. Perindopril (Coversyl)--a new ACE inhibitor. Perindopril--a review of its pharmacokinetics and clinical pharmacology.
    Reid JL; Macfadyen RJ; Lees KR
    S Afr Med J; 1991 Oct; Suppl():1-5. PubMed ID: 1925812
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of perindopril (prestarium) in arterial hypertension].
    Filatova NP
    Ter Arkh; 1995; 67(9):81-3. PubMed ID: 7495054
    [No Abstract]   [Full Text] [Related]  

  • 3. Perindopril. A review of its pharmacokinetics and clinical pharmacology.
    Macfadyen RJ; Lees KR; Reid JL
    Drugs; 1990; 39 Suppl 1():49-63. PubMed ID: 2407493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Symposium on future prospects of angiotensin converting enzyme. Presentation of perindopril, a new and potent ACE inhibitor. Perindopril exerts an efficacious and rapid inhibition of ACE in plasma as well as in tissues].
    Med Clin (Barc); 1991 Apr; 96(16):suppl 2 p.. PubMed ID: 2051826
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.
    Sennesael J; Ali A; Sweny P; Vandenburg M; Slovic D; Dratwa M; Resplandy G; Genissel P; Desche P
    Br J Clin Pharmacol; 1992 Jan; 33(1):93-9. PubMed ID: 1311597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effect of perindopril: experimental pharmacology.
    Barthelmebs M; Devissaguet M; Imbs JL
    Clin Exp Hypertens A; 1989; 11 Suppl 2():471-86. PubMed ID: 2691126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of perindopril: therapeutic consequences.
    Lees KR; Hughes DM; McNeill CA; Reid JL
    Clin Exp Hypertens A; 1989; 11 Suppl 2():499-506. PubMed ID: 2605799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril.
    Lees KR; Green ST; Reid JL
    Clin Pharmacol Ther; 1988 Oct; 44(4):418-25. PubMed ID: 2844467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of perindopril.
    Lees KR
    J Hum Hypertens; 1990 Oct; 4 Suppl 4():7-8; discussion 9-11. PubMed ID: 2283658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
    Sami M
    Can J Cardiol; 1999 May; 15 Suppl C():19C-23C. PubMed ID: 10380688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study PROTECT (Perindopril Regression of Vascular Thickening). European Community Trial].
    Tarentini Trojani F
    Clin Ter; 1994 Nov; 145(11):411-2. PubMed ID: 7889727
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antihypertensive effect of perindopril. Experimental pharmacology].
    Barthelmebs M; Devissaguet M; Imbs JL
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():17-24. PubMed ID: 2505709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of perindopril on the renal haemodynamic changes associated with adaptation to sodium restriction in the rat.
    Jover B; Dupont M; Mimran A
    J Hypertens Suppl; 1988 Dec; 6(3):S75-7. PubMed ID: 2852238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.
    Todd PA; Fitton A
    Drugs; 1991 Jul; 42(1):90-114. PubMed ID: 1718688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacology of angiotensin II receptor antagonists].
    Hitzenberger G
    Wien Med Wochenschr; 2001; 151(7-8):151-2. PubMed ID: 11450161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form].
    Václavík J
    Vnitr Lek; 2013 Apr; 59(4):290-4. PubMed ID: 23711055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting ex vivo inhibition by perindopril of rat vascular response to angiotensin I.
    Ishigai Y; Fukuzawa A; Chiba K; Irie K; Shibano T
    Methods Find Exp Clin Pharmacol; 1994 Nov; 16(9):633-8. PubMed ID: 7746024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [International experts commented on the characteristics of perindopril, a new highly potent and well tolerated ACE. Perindopril has been able to reduce the thickness and rigidity of the arterial wall in animal studies].
    Med Clin (Barc); 1991 May; 96(19):suppl 2 p.. PubMed ID: 1875747
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of perindopril on angiotensin converting enzyme in tissues of the rat.
    Jackson B; Cubela RB; Johnston CI
    J Hypertens Suppl; 1988 Dec; 6(3):S51-4. PubMed ID: 2852236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.